RxDoctor Payments Data

David Huff, DO

Family Medicine · Ovid, MINPI 1568491397

Payments from drug & device makers

$1,202in general payments, 2019–2025

Across 77 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$361
  • Sunovion Pharmaceuticals Inc.$214
  • Amgen$101
  • Sanofi-aventis U.S. LLC$94
  • Johnson & Johnson$67
  • AbbVie$61
  • plus $303 from 8 others

What the payments were for

  • Food & beverage$1,202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,202 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$42,202
Medicare patients
213
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$115,605
OzempicSemaglutide84$101,602
TrulicityDulaglutide45$43,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$37,972
JanuviaSitagliptin Phosphate23$33,040
JardianceEmpagliflozin20$31,181
XareltoRivaroxaban32$28,884
MounjaroTirzepatide17$24,621
Tiotropium Bromide14$17,580
FarxigaDapagliflozin Propanediol15$17,019
Breo ElliptaFluticasone/Vilanterol28$14,644
Lurasidone Hcl24$7,778
Rosuvastatin Calcium441$7,504
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$7,490
Tresiba Flextouch U-100Insulin Degludec11$7,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$115,605116 claims
Novo NordiskOzempic$61$101,60284 claims
GSKTrelegy Ellipta, Breo Ellipta$43$52,61578 claims
MerckJanuvia$44$33,04023 claims
Boehringer IngelheimJardiance$15$31,18120 claims
Johnson & JohnsonXarelto$67$28,88432 claims
AstraZenecaFarxiga, Symbicort$361$19,36226 claims
Sanofi-aventis U.S. LLCLantus$94$3,52618 claims
AbbVieArmour Thyroid$61$2,07122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Ovid

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →